Congenital retinal arteriovenous communication Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

📰

1Recent news

Regulatory Watchboard

No FDA or trial events recorded yet for Congenital retinal arteriovenous communication.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Congenital retinal arteriovenous communication.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

TOBRADEX ST

(TOBRAMYCIN / DEXAMETHASONE)standard

Harrow Eye, LLC

Corticosteroid [EPC]

12.1 Mechanism of Action Dexamethasone is a potent corticoid. Corticoids suppress the inflammatory response to a variety of agents and they can delay ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Congenital retinal arteriovenous communication.
Search all trials →

Search clinical trials for Congenital retinal arteriovenous communication →

Recent News & Research

1 article

BREAKINGFDA

FDA Approves TOBRADEX ST

TOBRADEX ST (DEXAMETHASONE) received FDA approval.

Read ↗

Browse all Congenital retinal arteriovenous communication news →

Specialist Network

No specialists currently listed for Congenital retinal arteriovenous communication.

View all Congenital retinal arteriovenous communication specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰